Shire PLC (LON:SHP) had its price target cut by research analysts at Jefferies Group LLC from GBX 5,600 ($73.87) to GBX 5,250 ($69.25) in a research note issued to investors on Monday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target would indicate a potential upside of 30.65% from the stock’s current price.

Several other equities analysts have also issued reports on the company. Citigroup Inc. reissued a “buy” rating and issued a GBX 6,500 ($85.74) price target on shares of Shire PLC in a research note on Wednesday, May 17th. HSBC Holdings plc raised Shire PLC to a “hold” rating and set a GBX 4,450 ($58.70) price target on the stock in a research note on Thursday, July 6th. Credit Suisse Group reissued an “outperform” rating and issued a GBX 5,400 ($71.23) price target on shares of Shire PLC in a research note on Wednesday, April 19th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a GBX 6,800 ($89.70) price target on shares of Shire PLC in a research note on Wednesday, May 3rd. Finally, Deutsche Bank AG dropped their price target on Shire PLC from GBX 6,300 ($83.10) to GBX 6,100 ($80.46) and set a “buy” rating on the stock in a research note on Wednesday, May 10th. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of GBX 5,937.29 ($78.32).

Shares of Shire PLC (LON SHP) opened at 3994.00 on Monday. Shire PLC has a 1-year low of GBX 3,981.50 and a 1-year high of GBX 5,377.00. The company’s 50-day moving average price is GBX 4,283.27 and its 200-day moving average price is GBX 4,548.83. The company’s market capitalization is GBX 36.11 billion.

ILLEGAL ACTIVITY NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/08/07/shire-plc-lonshp-price-target-lowered-to-gbx-5250-at-jefferies-group-llc.html.

In related news, insider Dominic Blakemore purchased 152 shares of the firm’s stock in a transaction that occurred on Friday, June 30th. The stock was acquired at an average price of GBX 4,255 ($56.13) per share, for a total transaction of £6,467.60 ($8,531.33).

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (LON:SHP)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.